Stockreport

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio, Inc.  (IBRX) 
PDF ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two clinical trials in 151 patients with non-small cell [Read more]